Analysts See $0.19 EPS for LeMaitre Vascular, Inc. (LMAT)

January 21, 2018 - By Dolores Ford

 Analysts See $0.19 EPS for LeMaitre Vascular, Inc. (LMAT)
Investors sentiment is 1.71 in 2017 Q3. Its the same as in 2017Q2. It is the same, as 11 investors sold LeMaitre Vascular, Inc. shares while 38 reduced holdings. only 27 funds opened positions while 57 raised stakes. 13.06 million shares or 7.12% more from 12.19 million shares in 2017Q2 were reported.
Fiduciary reported 0.02% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Tiaa Cref Mngmt Lc invested in 125,554 shares. Tower Lc (Trc) has 1,981 shares. Yorktown Management And Rech Inc has 0.07% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 6,825 shares. Schwab Charles Invest Mngmt Inc accumulated 65,477 shares. State Of Alaska Department Of Revenue reported 2,968 shares. Ameriprise Inc holds 0% or 199,273 shares in its portfolio. Martingale Asset Mngmt L P holds 0.03% in LeMaitre Vascular, Inc. (NASDAQ:LMAT) or 50,101 shares. Credit Suisse Ag stated it has 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Texas-based Ranger Invest Lp has invested 1.11% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Congress Asset Mgmt Ma owns 40,287 shares for 0.02% of their portfolio. Koch Industries stated it has 0.05% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Globeflex Limited Partnership invested in 0.83% or 78,077 shares. Thrivent Financial For Lutherans holds 9,180 shares or 0% of its portfolio. Nationwide Fund Advsrs stated it has 120,793 shares or 0.02% of all its holdings.

Since August 1, 2017, it had 0 buys, and 11 insider sales for $11.10 million activity. On Wednesday, August 30 Roberts David B sold $978,479 worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) or 26,683 shares. Gebauer Peter R also sold $210,671 worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) shares. $224,064 worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) shares were sold by Jasinski Lawrence J.

Analysts expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to report $0.19 EPS on February, 20.They anticipate $0.06 EPS change or 46.15 % from last quarter’s $0.13 EPS. LMAT’s profit would be $3.66 million giving it 43.63 P/E if the $0.19 EPS is correct. After having $0.25 EPS previously, LeMaitre Vascular, Inc.’s analysts see -24.00 % EPS growth. The stock increased 1.04% or $0.34 during the last trading session, reaching $33.16. About 79,240 shares traded. LeMaitre Vascular, Inc. (NASDAQ:LMAT) has risen 101.07% since January 21, 2017 and is uptrending. It has outperformed by 84.37% the S&P500.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Ratings Coverage

Among 11 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. LeMaitre Vascular had 35 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Cowen & Co on Thursday, April 21. The rating was downgraded by Sidoti on Thursday, September 22 to “Neutral”. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) has “Buy” rating given on Friday, October 27 by Stifel Nicolaus. The rating was maintained by Barrington Research with “Outperform” on Thursday, February 25. The rating was downgraded by Canaccord Genuity to “Hold” on Monday, July 10. The firm earned “Hold” rating on Monday, July 10 by Benchmark. The rating was downgraded by Benchmark to “Hold” on Friday, October 27. TH Capital maintained it with “Buy” rating and $14 target in Wednesday, July 29 report. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) earned “Buy” rating by Roth Capital on Friday, July 28. The rating was maintained by TH Capital with “Buy” on Monday, December 7.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company has market cap of $638.82 million. The firm provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins. It has a 42.46 P/E ratio. It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature.

More notable recent LeMaitre Vascular, Inc. (NASDAQ:LMAT) news were published by: Seekingalpha.com which released: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q2 2017 Results – Earnings …” on July 28, 2017, also Nasdaq.com with their article: “LeMaitre Vascular, Inc. (LMAT) Ex-Dividend Date Scheduled for August 21, 2017” published on August 18, 2017, Globenewswire.com published: “LeMaitre Vascular to Present at Upcoming November and December Investor …” on November 01, 2017. More interesting news about LeMaitre Vascular, Inc. (NASDAQ:LMAT) were released by: Globenewswire.com and their article: “LeMaitre Vascular Will Announce Second Quarter 2017 Earnings Results on July …” published on July 13, 2017 as well as Seekingalpha.com‘s news article titled: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q1 2017 Results – Earnings …” with publication date: April 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: